Phase II trial of Trastuzumab + CPT-11 therapy for HER2-positive advanced gastric cancer patients with prior chemotherapy

Trial Profile

Phase II trial of Trastuzumab + CPT-11 therapy for HER2-positive advanced gastric cancer patients with prior chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2016

At a glance

  • Drugs Irinotecan (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-5
  • Most Recent Events

    • 07 Aug 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Aug 2013 Actual initiation date changed from Aug 2012 to 12 Oct 2012 as reported by University Hospital Medical Information Network - Japan record.
    • 13 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top